Propensity score-matched analysis
| Variable | Extrahepatic group (n=173) | Intrahepatic group (n=173) | P value |
| Age (years) | 66.11±10.63 | 64.00±11.46 | 0.077 |
| Age | 0.489 | ||
| ≤60 years | 52 (30.06%) | 58 (33.53%) | |
| >60 years | 121 (69.94%) | 115 (66.47%) | |
| Sex | 0.738 | ||
| Male | 108 (62.43%) | 111 (64.16%) | |
| Female | 65 (37.57%) | 62 (35.84%) | |
| Race | 0.424 | ||
| Black | 3 (1.73%) | 3 (1.73%) | |
| White | 151 (87.28%) | 143 (82.66%) | |
| Others | 19 (10.98%) | 27 (15.61%) | |
| Marital status | 0.594 | ||
| Single | 43 (24.86%) | 41 (23.70%) | |
| Married | 124 (71.68%) | 129 (74.57%) | |
| Unknown | 6 (3.47%) | 3 (1.73%) | |
| Differentiation | 0.488 | ||
| Grade I | 18 (10.40%) | 18 (10.40%) | |
| Grade II | 69 (39.88%) | 81 (46.82%) | |
| Grade III | 39 (22.54%) | 38 (21.97%) | |
| Unknown | 47 (27.17%) | 36 (20.81%) | |
| AJCC clinical stage | 0.233 | ||
| Stage I | 86 (49.71%) | 82 (47.40%) | |
| Stage II | 8 (4.62%) | 10 (5.78%) | |
| Stage III | 45 (26.01%) | 60 (34.68%) | |
| Stage IV | 22 (12.72%) | 13 (7.51%) | |
| Unknown | 12 (6.94%) | 8 (4.62%) | |
| T stage | 0.196 | ||
| T1 | 89 (51.45%) | 91 (52.60%) | |
| T2 | 9 (5.20%) | 14 (8.09%) | |
| T3 | 14 (8.09%) | 5 (2.89%) | |
| T4 | 49 (28.32%) | 54 (31.21%) | |
| Tx | 12 (6.94%) | 9 (5.20%) | |
| N stage | 0.894 | ||
| N0 | 128 (73.99%) | 130 (75.14%) | |
| N1 | 40 (23.12%) | 37 (21.39%) | |
| Nx | 5 (2.89%) | 6 (3.47%) | |
| M stage | 0.276 | ||
| M0 | 148 (85.55%) | 156 (90.17%) | |
| M1 | 22 (12.72%) | 13 (7.51%) | |
| Mx | 3 (1.73%) | 4 (2.31%) | |
Bold P values indicate that the corresponding item has statistical significance.
AJCC, American Joint Committee on Cancer.